Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

B. Henick · SciRah

Researcher profile · Semantic Scholar

B. Henick

Share profile

B. Henick — researcher profile on SciRah

h-index: 23
Works: 135
Citations: 3,762

Most-cited papers

Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
B. Ricciuti, Xinan Wang, J. Alessi, H. Rizvi +34 more
2022JAMA Oncology321 citations Open access
Semantic Scholar
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results
C. Palmer, Amy R. Rappaport, Matthew J. Davis, M. Hart +40 more
2022Nature Medicine214 citations Open access
Semantic Scholar
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Arvind Ravi, M. Hellmann, Monica B. Arniella, Mark Holton +38 more
2023Nature Genetics171 citations Open access
Semantic Scholar
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results
A. Rappaport, C. Kyi, Monica Lane, Meghan G. Hart +34 more
2024Nature Medicine141 citations
Semantic Scholar
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
Juanita S. Lopez, T. Powles, F. Braiteh, L. Siu +76 more
2025Nature Medicine104 citations Open access
Semantic Scholar
Single-cell and spatial genomic landscape of non-small cell lung cancer brain metastases
Somnath Tagore, Lindsay A. Caprio, Amit Dipak Amin, K. Bestak +46 more
2025Nature Medicine70 citations Open access
Semantic Scholar
Multi-modal single-cell and whole-genome sequencing of small, frozen clinical specimens
Yi-Ping Wang, J. L. Fan, Johannes C. Melms, A. Amin +21 more
2023Nature Genetics54 citations Open access
Semantic Scholar
Anticancer Therapy Targeting Cancer-Derived Extracellular Vesicles.
Xiao Cheng, B. Henick, Ke Cheng
2024ACS Nano44 citations
Semantic Scholar
A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies
P. Mundi, F. D. Dela Cruz, A. Grunn, Daniel Diolaiti +51 more
2023Cancer Discovery41 citations Open access
Semantic Scholar
BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.
M. Patel, D. Juric, B. Henick, L. Duska +6 more
2023Journal of Clinical Oncology30 citations Open access
Semantic Scholar
Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
B. Wilky, Gary K. Schwartz, M. Gordon, A. El-Khoueiry +16 more
2025Journal of Clinical Oncology22 citations Open access
Semantic Scholar
BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2− breast cancer (BC).
D. Juric, M. Patel, L. Duska, K. Jhaveri +13 more
2024Journal of Clinical Oncology19 citations Open access
Semantic Scholar
Self-Renewing CD8+ T-Cell Abundance in Blood Associates with Response to Immunotherapy
R. Maniar, Peter H. Wang, R. Washburn, R. Kratchmarov +8 more
2022Cancer immunology research18 citations Open access
Semantic Scholar
Squamous cell cancers of the aero-upper digestive tract: a unified perspective on biology, genetics and therapy
B. Henick, Alison M. Taylor, Hiroshi Nakagawa, Kwok K. Wong +2 more
2025Cancer Cell17 citations Open access
Semantic Scholar
Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity
Xi-Zi Hu, Shoiab Bukhari, Carly C. Tymm, Kieran R. Adam +4 more
2024Journal for ImmunoTherapy of Cancer17 citations Open access
Semantic Scholar
Tumor-derived CCL5 recruits cancer-associated fibroblasts and promotes tumor cell proliferation in esophageal squamous cell carcinoma
Karen J. Dunbar, Tatiana A. Karakasheva, Qiaosi Tang, Gizem Efe +10 more
2023Molecular Cancer Research17 citations Open access
Semantic Scholar
PRAGMATICA-LUNG (SWOG S2302): A prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer.
K. Dragnev, M. Redman, K. Reckamp, M. Khalil +13 more
2025Journal of Clinical Oncology15 citations
Semantic Scholar
Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells
Matthieu Paiola, Daniel M Portnoy, Lu-Ke Hao, Shoiab Bukhari +4 more
2025Journal for ImmunoTherapy of Cancer14 citations Open access
Semantic Scholar
Advancements in TGF-β Targeting Therapies for Head and Neck Squamous Cell Carcinoma
William Britton, Isabel Cioffi, Corinne Stonebraker, Matthew Spence +5 more
2024Cancers13 citations Open access
Semantic Scholar
Abstract CT034: GLIMMER-01: initial results from a phase 1 dose escalation trial of a first-in-class bi-sialidase (E-602) in solid tumors
J. Luke, Melissa Johnson, A. Tolcher, Christopher T. Chen +14 more
2023Cancer Research13 citations
Semantic Scholar
Patient-Derived Three-Dimensional Culture Techniques to Model Tumor Heterogeneity in Head and Neck Cancer
Anuraag S. Parikh, Victoria X. Yu, Samuel P. Flashner, Ogoegbunam Okolo +7 more
2023Oral Oncology13 citations Open access
Semantic Scholar
Pragmaticism in Cancer Clinical Trials.
Kamya Sankar, M. Redman, K. Dragnev, B. Henick +5 more
2024American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting12 citations
Semantic Scholar
Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer
B. Henick, F. Villarroel-Espíndola, I. Datar, M. Sanmamed +9 more
2022Journal for ImmunoTherapy of Cancer12 citations Open access
Semantic Scholar
758 GLIMMER-01: phase 1/2 trial of a first-in-class bi-sialidase (E-602) in combination with cemiplimab in patients with PD-(L)1-resistant solid tumors
Manish R. Sharma, Melissa L. Johnson, I. Puzanov, Mario Sznol +16 more
2024Regular and Young Investigator Award Abstracts10 citations Open access
Semantic Scholar
Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings
B. Henick, Peter D. Koch, J. Gainor, M. Awad +14 more
2024Journal for ImmunoTherapy of Cancer10 citations Open access
Semantic Scholar
PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritis
Johanna Straube, Shoiab Bukhari, Shalom Lerrer, Robert J. Winchester +4 more
2024Arthritis Research & Therapy9 citations Open access
Semantic Scholar
DB-1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC).
A. Parsonson, Chintan Gandhi, B. Henick, Andrew Schmidt +16 more
2025Journal of Clinical Oncology8 citations Open access
Semantic Scholar
Ethnic diversity in treatment response for colorectal cancer: proof of concept for radiomics-driven enrichment trials
L. Dercle, Melissa Yang, M. Gönen, J. Flynn +10 more
2023European Radiology8 citations
Semantic Scholar
SWOG S2302, PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (PR) versus standard of care (SOC) for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer.
K. Reckamp, M. Redman, K. Dragnev, W. Iams +7 more
2024Journal of Clinical Oncology7 citations Open access
Semantic Scholar
736MO Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS)
C. Kyi, A. Spira, D. P. Carbone, M. L. Johnson +15 more
2022Annals of Oncology6 citations Open access
Semantic Scholar
Abstract CT183: Initial results from a phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132)
B. Izar, D. Zamarin, D. Spigel, C. Hoimes +17 more
2024Cancer Research5 citations
Semantic Scholar
Effects of mutations in SWI/SNF subunits on context-specific prognosis in driver positive and driver negative NSCLC.
B. Herzberg, N. Gandhi, B. Henick, J. Xiu +3 more
2023Journal of Clinical Oncology5 citations
Semantic Scholar
Weight loss in patients on osimertinib for metastatic EGFR-mutant non-small cell lung cancer
L. Chen, Xin Ma, B. Herzberg, B. Henick +3 more
2024The Oncologist4 citations Open access
Semantic Scholar
772 A phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01)
Manish R. Sharma, D. Lathers, M. Johnson, J. Luke +16 more
2022Regular and Young Investigator Award Abstracts4 citations Open access
Semantic Scholar
The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non–small cell lung cancer
Margaux Wooster, Michael S. May, Prashasti Agrawal, Jonathan W. Lee +12 more
2025Journal of the National Cancer Institute3 citations Open access
Semantic Scholar
Abstract CT226: Phase 2 study of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with head and neck squamous cell carcinoma (HNSCC) previously treated with checkpoint inhibitor
J. Muzaffar, K. Kirtane, Rebecca Redman, Muh-Hwa Yang +15 more
2024Cancer Research3 citations
Semantic Scholar
1919MO Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma
B. Wilky, J. C. Trent, M. Gordon, A. El-Khoueiry +10 more
2023Annals of Oncology3 citations Open access
Semantic Scholar
VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor (CDK4/6i)-resistant advanced solid tumors (1275)
Timothy Yap, Manisha Patel, B. Henick, K. Moore +8 more
2023Gynecologic Oncology3 citations
Semantic Scholar
Abstract CT217: 3-year update of neoadjuvant atezolizumab + chemotherapy in patients with resectable non-small cell lung cancer
B. Henick, J. Gainor, M. Awad, C. Chiuzan +12 more
2023Cancer Research3 citations
Semantic Scholar
PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritis
Johanna Straube, Shoiab Bukhari, Shalom Lerrer, Robert J. Winchester +3 more
2023bioRxiv3 citations Open access
Semantic Scholar
Multi-modal single-cell and whole-genome sequencing of minute, frozen specimens to propel clinical applications
Yi-Ping Wang, J. L. Fan, Johannes C. Melms, A. Amin +16 more
2022bioRxiv3 citations Open access
Semantic Scholar
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors
K. Rohrberg, I. Melero, M. Sanmamed, Eva Muñoz-Couselo +35 more
2026Journal for ImmunoTherapy of Cancer2 citations Open access
Semantic Scholar
Translational inhalable extracellular vesicle‐based mRNA therapy for the treatment of lung cancer
Meng-Rui Liu, B. Henick, Ke Cheng
2025Clinical and Translational Medicine2 citations Open access
Semantic Scholar
Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors.
S. Thomas, Brian Pico, B. Henick, R. Leidner +14 more
2024Journal of Clinical Oncology2 citations
Semantic Scholar
Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.
S. Gettinger, F. Wilson, S. Goldberg, A. Chiang +11 more
2023Journal of Clinical Oncology2 citations
Semantic Scholar
Abstract OT3-23-01: VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor-resistant advanced solid tumors
M. Patel, D. Juric, B. Henick, K. Moore +7 more
2023Cancer Research2 citations
Semantic Scholar
An RNA-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment Resistant Malignancies
P. Mundi, F. D. Dela Cruz, A. Grunn, Daniel Diolaiti +50 more
2022Social Science Research Network2 citations Open access
Semantic Scholar
A global, phase 1/2 study of DB-1311/BNT324 (a novel B7H3 ADC) monotherapy in patients with previously treated advanced cervical cancer or platinum-resistant recurrent ovarian cancer: Outcomes by prior treatment
I. Winer, B. Gao, Chih-Long Chang, L. Corke +17 more
2026Gynecologic Oncology1 citations
Semantic Scholar
DB-1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated mCRPC from a phase 1/2 study: Analyses according to prior treatment with lutetium 177 (177Lu)-PSMA-617.
Mark N. Stein, A. Parsonson, T. Gourdin, B. Henick +16 more
2026Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Female sex is associated with worse survival in laryngeal head and neck squamous cell carcinoma
Alexandria G. Yao, Amber Arif, Chloe Paolucci, Sejal Jain +6 more
2026The Oncologist1 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. Rizvi×6
Invite
N. Rizvi — researcher profile on SciRah
Yohanna Georgis×5
Invite
Yohanna Georgis — researcher profile on SciRah
A. El-Khoueiry×5
Invite
A. El-Khoueiry — researcher profile on SciRah
K. Schalper×4
Invite
K. Schalper — researcher profile on SciRah

×4

Invite

B. Herzberg — researcher profile on SciRah

Benjamin Izar×4

Invite

Benjamin Izar — researcher profile on SciRah

Invite

G. Schwartz — researcher profile on SciRah

Invite

R. Carvajal — researcher profile on SciRah

Invite

C. Shu — researcher profile on SciRah

Invite

D. Juric — researcher profile on SciRah

Mikael L Rinne×4

Invite

Mikael L Rinne — researcher profile on SciRah

Shoiab Bukhari×4

Invite

Shoiab Bukhari — researcher profile on SciRah